Established in: 1884
CEO: Mohit Malhotra
Dabur India Limited is a multinational consumer goods producing company headquartered in Ghaziabad. The company was established in 1884 in Kolkata by S. K. Burman and is engaged in producing Ayurvedic products and FMCG, such as health supplements, personal care, food and beverages, and skin care, etc.
Dabur India Limited launched its IPO and went public in 1994, with the issue being oversubscribed 21 times. The company is now listed on the BSE and the NSE under the ticker symbols 500096 and DABUR, respectively.
History of Dabur India Limited
Dabur India Limited was founded in 1884 as an ayurvedic medicines company by Dr S.K. Burman with the mission to produce healthcare products in Kolkata. As the company started gaining popularity, it set up a manufacturing plant for mass production of formulations. In the following years, the company expanded significantly, establishing research laboratories and setting up new manufacturing units.
In 1936, Dabur evolved into a mature company called Dabur India (Dr. S. K. Burman) Pvt. Ltd. The company shifted its operations to Delhi and set up manufacturing plans in the outskirts of the city. It started its commercial production in the Sahibabad factory and established Dabur Research & Development Centre (DRDC).
In 1986, Dabur became a public limited company. It entered into a joint venture with Agrolimen of Spain to manufacture and sell confectionery items in India. In 1993, Dabur entered the cancer treatment field and set up its oncology formulation plant in Himachal Pradesh.
In 1994, Dabur India Limited went public, and its IPO was a remarkable success. In the following years, the company expanded significantly by entering into joint ventures, setting up domestic and international subsidiaries and entering new markets.
Business Segments of Dabur India Limited
The following are the business segments of Dabur India Limited.
This business segment is the company's biggest revenue driver and is further divided into two categories: Health care and Home and Personal Care. The health care segment focuses on Ayurvedic and Over-The-Counter products such as Dabur Chyawanprash, Dabur honey, and Dabur Pudin Hara, etc. Whereas, the Home and Personal Care segment manufactures and markets products such as Dabur Amla and Dabur Red Paste.
This business segment produces and markets packaged fruit juices and drinks, along with culinary pastes and packaged foods under its label. Dabur India Limited acquired Badshah Masala to expand its food and beverage portfolio.
The company caters to international markets through its overseas subsidiaries, offering a wide range of products under the brand names ‘Vatika’, ‘Dabur Amla’, ‘Hobi Group’, and ‘ORS’.
Subsidiaries of Dabur India Limited
The following are the subsidiaries of Dabur India Limited.
- African Consumer Care Limited in Nigeria
- Asian Consumer Care Pakistan Pvt. Ltd. in Pakistan
- Asian Consumer Care Pvt Ltd. in Bangladesh
- Dabur (UK) Ltd. in the British Virgin Islands
- Dabur Consumer Care (Private) Limited in Srilanka
- Dabur Egypt Ltd. in Egypt
- Dabur International Ltd.
- Dabur Lanka (Pvt.) Ltd in Sri Lanka
- Dabur Nepal Pvt. Ltd. in Nepal
- Dabur Pakistan Pvt. Ltd. in Pakistan
- Dabur Pars in Iran
- Dabur South Africa Pty. Ltd. in South Africa
- Dabur Tunisie in Tunisia
- Dermoviva Skin Essentials Inc. in the USA
- H & B Stores Limited
- Hair Rejuvenation & Revitalisation Nigeria Ltd. in Nigeria
- Healing Hair Lab International LLC in the USA
- Hobi Kozmetik in Turkey
- Namaste Laboratories LLC in the USA
- Naturelle LLC in the UAE
- RA Pazarlama in Turkey
- Urban Lab International LLC in the USA
Dabur India Financial Highlights
- Revenue: Dabur India reported revenue of ₹13,792.34 crore in FY26 vs ₹13,113.19 crore in FY25. It showed an increase of 5.18% on a yearly basis.
- Operating Profit: Dabur India reported an operating profit of ₹2,420.43 crore in FY26 vs ₹2,257.89 crore in FY25. It showed an increase of 7.20% on a year-on-year basis.
- Net Profit: Dabur India reported a net profit of ₹1,868.69 crore in FY26 vs ₹1,740.42 crore in FY25. It showed an increase of 7.37% on a yearly basis.
Dabur India Quarterly Result Highlights
- Dabur India reported revenue of ₹3,213.05 crore in Mar 2026, compared with ₹3,699.29 crore in Dec 2025, representing a decrease of 13.14% on a quarter-on-quarter (QoQ) basis.
- Dabur India reported an operating profit of ₹473.68 crore in Mar 2026, compared with ₹711.11 crore in Dec 2025, representing a decrease of 33.39% on a quarter-on-quarter (QoQ) basis.
- Dabur India reported a profit of ₹362.00 crore in Mar 2026, compared with ₹553.61 crore in Dec 2025, reflecting a decrease of 34.61% on a QoQ basis.
- The earnings per share (EPS) of Dabur India stood at ₹10.69 during Mar 2026.
